Vanda Pharmaceuticals (VNDA) News Today → Bill Gates is all about this tiny $2 stock (From Timothy Sykes) (Ad) Free VNDA Stock Alerts $5.11 +0.10 (+2.00%) (As of 05/31/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 4:08 AM | americanbankingnews.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 21.7% in MayMay 31 at 8:09 PM | marketbeat.comShort Interest in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Rises By 21.7%Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 2,800,000 shares, an increase of 21.7% from the April 30th total of 2,300,000 shares. Currently, 5.1% of the shares of the stock are short sold. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is presently 1.2 days.May 30, 2024 | prnewswire.comVanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare ConferenceMay 30, 2024 | prnewswire.comVanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®May 29, 2024 | prnewswire.comVanda Pharmaceuticals Announces Presentations at SLEEP 2024May 24, 2024 | marketwatch.comVanda Pharma Rejects Future Pak's Sweetened Takeover BidMay 24, 2024 | msn.comVanda Pharmaceuticals rejected sweetened bid from Future PakMay 24, 2024 | prnewswire.comVanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its ShareholdersMay 20, 2024 | marketbeat.comAssenagon Asset Management S.A. Cuts Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Assenagon Asset Management S.A. lessened its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 54.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 730,820 shares of the biopharmaceutical company's stock after sellinMay 15, 2024 | markets.businessinsider.comVanda Pharma Reports Positive Results From Second Phase III Study Of TradipitantMay 15, 2024 | msn.comVanda reports positive Phase 3 data for motion sickness drugMay 15, 2024 | prnewswire.comVanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion SicknessMay 10, 2024 | finance.yahoo.comVanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue EstimatesMay 9, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comVanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 9, 2024 | finance.yahoo.comQ1 2024 Vanda Pharmaceuticals Inc Earnings CallMay 8, 2024 | msn.comVanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46MMay 8, 2024 | markets.businessinsider.comVNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comVanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finanznachrichten.deVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakMay 7, 2024 | markets.businessinsider.comVanda Pharma Receives Revised Unsolicited Takeover Proposal From Future PakMay 7, 2024 | msn.comVanda Pharmaceuticals up 15% as Future Pak sweetens bidMay 7, 2024 | prnewswire.comVanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakMay 7, 2024 | finance.yahoo.comUPDATE 2-Future Pak sweetens take-private offer for Vanda PharmaceuticalsMay 7, 2024 | businesswire.comFuture Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in CashMay 1, 2024 | marketbeat.comVanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on WednesdayVanda Pharmaceuticals (NASDAQ:VNDA) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.April 30, 2024 | prnewswire.comVanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024April 25, 2024 | finance.yahoo.comUPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offerApril 25, 2024 | reuters.comShareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offerApril 25, 2024 | finance.yahoo.comShareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsApril 24, 2024 | finance.yahoo.comVanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should KnowApril 22, 2024 | prnewswire.comVanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationApril 22, 2024 | msn.comUS Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, HetliozApril 22, 2024 | msn.comU.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patentsApril 22, 2024 | msn.comUS Supreme Court reportedly declines to hear Vanda patent caseApril 19, 2024 | reuters.comButler Hall Capital urges Vanda to engage in sales discussionsApril 18, 2024 | finance.yahoo.comFuture Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in CashApril 18, 2024 | bizjournals.comD.C. biotech adopts poison pill after rejecting acquisition offerApril 18, 2024 | markets.businessinsider.comVanda Pharma Adopts Limited Duration Stockholder Rights Plan; Stock UpApril 17, 2024 | benzinga.comWhy Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionApril 17, 2024 | msn.comBiggest stock movers today: ADSK, VNDA, UAL, JBHT, and moreApril 17, 2024 | markets.businessinsider.comCrude Oil Dips 3%; U.S. Bancorp Profit Tops ViewsApril 17, 2024 | finance.yahoo.comNeuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/ShareApril 17, 2024 | fool.comWhy Vanda Pharmaceuticals Stock Is Skyrocketing TodayApril 17, 2024 | prnewswire.comVanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanApril 17, 2024 | msn.comVanda Pharmaceuticals (VNDA) Price Target Increased by 23.53% to 5.36April 17, 2024 | markets.businessinsider.comVanda Pharma Rejects Future Pak's Takeover Proposals; Stock ClimbsApril 17, 2024 | msn.comVanda Pharmaceuticals jumps 38% on Future Pak's latest buy offerApril 17, 2024 | msn.comWhy Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today? Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately. VNDA Media Mentions By Week VNDA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNDA News Sentiment▼0.540.76▲Average Medical News Sentiment VNDA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNDA Articles This Week▼73▲VNDA Articles Average Week Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XOMA News Today Verastem News Today Emergent BioSolutions News Today Lexicon Pharmaceuticals News Today Rigel Pharmaceuticals News Today Gossamer Bio News Today Regulus Therapeutics News Today VBI Vaccines News Today AnaptysBio News Today OPKO Health News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VNDA) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Gates is all about this tiny $2 stockTimothy SykesBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTradeShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.